---
title: "Novo Nordisk A/S (NVO.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NVO.US/overview.md"
symbol: "NVO.US"
name: "Novo Nordisk A/S"
parent: "https://longbridge.com/en/quote/NVO.US.md"
datetime: "2026-04-17T08:40:37.381Z"
locales:
  - [en](https://longbridge.com/en/quote/NVO.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NVO.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NVO.US/overview.md)
---

# Novo Nordisk A/S (NVO.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Address | Novo Alle 1, Bagsvaerd, Capital Region of Denmark, Denmark |
| Website | [www.novonordisk.com](https://www.novonordisk.com) |

## Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.

## Key Executives

| Name | Title |
|------|-------|
| Karsten Munk Knudsen | Executive VP, CFO & Member of the Management Board |
| Lars Rebien Sorensen | Chair of Board |
| Maziar Mike Doustdar | President, CEO & Member of the Management Board |
| Martin Holst Lange | EVP of R&D, Chief Scientific Officer and Member of the Management Board |
| Tania Sabroe | EVP of People, Organisation and Corporate Affairs & Member of Management Board |
| Thilde Hummel Bogebjerg | Executive VP of Enterprise IT & Quality and Member of Management Board |
| Cornelis de Jong | Independent Vice Chair of the Board |
| Stephan Engels | Independent Director |
| Desirée Jantzen Asgreen | Employee Representative Director |
| Mette Bojer Jensen | Employee Non-Independent Representative Director |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| Novo Holdings A/S | 28.23% | 2025-02-04 |
| BlackRock, Inc. | 4.08% | 2025-12-31 |
| The Vanguard Group, Inc. | 3.27% | 2026-02-28 |
| Norges Bank Investment Management | 1.61% | 2025-12-31 |
| Amundi Asset Management SAS | 0.62% | 2025-12-31 |
| Geode Capital Management, LLC | 0.60% | 2026-03-31 |
| State Street Global Advisors, Inc. | 0.41% | 2026-03-31 |
| JP Morgan Asset Management | 0.41% | 2026-03-31 |
| Loomis Sayles & Company, L.P. | 0.40% | 2026-01-31 |
| Deutsche Asset & Wealth Management | 0.40% | 2026-01-31 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Diabetes and Obesity Care | 289456000000 | 93.66% |
| Rare Disease | 19608000000 | 6.34% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Novo Nordisk A/S Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Diabetes and Obesity Care",
        "ratio": 93.66
      },
      {
        "segment": "Rare Disease",
        "ratio": 6.34
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## Geographic Segments

| Region | Revenue | Ratio |
|--------|---------|-------|
| United States of America (USA) | 173166000000 | 56.03% |
| Europe and Canada | 66091000000 | 21.38% |
| Emerging Markets | 30436000000 | 9.85% |
| APAC | 20713000000 | 6.7% |
| Region China | 18658000000 | 6.04% |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**